Bedrijfsoverzicht
DBV Technologies S.A. is a clinical-stage biopharmaceutical entity focused on the research and development of epicutaneous immunotherapy products within the French market. The company operates specifically in the healthcare sector and the biotechnology industry, which implies a focus on early-stage innovation and clinical validation rather than mature commercialization. DBV Technologies S.A. holds a market capitalization of $1.22B and reports annual revenue of $5.64M, while the employee count is listed as N/A in the provided data. The significant disparity between the market cap of $1.22B and the annual revenue of $5.64M indicates that the market is pricing the company based on the potential value of its product pipeline, particularly Viaskin Peanut, rather than current cash flows or sales performance.
Financiële gezondheid
The company generated revenue of $5.64M over the trailing twelve months, yet recorded a net income of $-146,947,008 and an EBITDA of $-143,862,000, revealing a cost structure where expenses significantly outweigh operating revenues. This substantial gap between the $5.64M in revenue and the $-146,947,008 net loss demonstrates that the business is burning cash rapidly to fund development activities before achieving commercial profitability. Free cash flow stands at $-64,285,000, which indicates a heavy reliance on external capital sources or cash reserves to sustain operations and fund R&D initiatives without generating internal liquidity. The gross margin is reported at 100.0%, suggesting that the cost of goods sold is negligible or fully covered by revenue at the current stage of production, while the operating margin of -6984.7% and profit margin of 0.0% highlight severe operational losses relative to sales. On the balance sheet, the company holds $194.17M in cash against $6.53M in debt, resulting in a debt-to-equity ratio of 3.87, which presents a complex picture of high leverage offset by substantial liquid assets. The current ratio of 3.67 suggests that the company possesses ample short-term assets to cover its current liabilities, providing a buffer against immediate liquidity pressures despite the negative earnings. Return on Equity is -149.8% and Return on Assets is -61.4%, metrics that reveal management is currently utilizing equity and assets to generate losses rather than positive returns, typical for a clinical-stage company but indicative of high financial risk until commercial milestones are reached.
Waarderingsbeoordeling
The trailing twelve-month P/E ratio is N/A due to negative earnings, while the forward P/E is -77.93, a valuation metric that implies investors are not pricing in immediate profitability but rather future earnings potential once the product launches. The price-to-book ratio stands at 5.75, indicating that the market values the company at a significant premium over its book value, likely reflecting the high intangible asset value associated with intellectual property and the clinical-stage nature of the business. Alternative valuation metrics such as the price-to-sales ratio of 216.21 and an EV/EBITDA of -32.41 suggest that valuation is driven entirely by revenue generation potential and pipeline value rather than profitability or earnings multiples. The 52-week high is $26.18 and the 52-week low is $7.00, meaning the stock has experienced substantial volatility within this trading range over the last year. With a beta of -0.20, the stock exhibits negative correlation to the broader market, meaning it tends to move inversely to the overall market index, which introduces a unique volatility profile distinct from standard healthcare equities.
Growth & Income
Revenue growth year-over-year is 26.2%, whereas earnings growth is N/A due to the lack of positive net income, implying that top-line expansion is occurring without corresponding bottom-line improvement in the current fiscal period. The company does not pay a dividend, evidenced by a dividend yield of N/A and a payout ratio of 0.0%, which confirms that all available cash is being reinvested into research, development, and operational scaling rather than distributed to shareholders. The absence of dividend payments aligns with the company's status as a clinical-stage biotechnology firm where capital allocation prioritizes advancing the Viaskin Peanut product through clinical trials. Overall, the growth and income profile is characterized by strong top-line expansion at 26.2% YoY but no current income generation, reflecting the high-risk, high-reward investment thesis typical of pre-revenue biopharmaceutical companies.